Phibro Animal Health Corp
NASDAQ:PAHC

  • LAST PRICE
    24.1400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    24.1400/ 2
  • Ask / Lots
    24.7600/ 1
  • Open / Previous Close
    --- / 24.1400
  • Day Range
    ---
  • 52 Week Range
    9.4900
    25.9800
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

  • Nov 12, 2024

  • Nov 6, 2024

      Show headlines and story abstract

    • 4:37PM ET on Wednesday Nov 06, 2024 by MT Newswires
      Companies Mentioned: PAHC
      04:37 PM EST, 11/06/2024 (MT Newswires) -- ...

    • 4:36PM ET on Wednesday Nov 06, 2024 by MT Newswires
      Companies Mentioned: PAHC
      04:36 PM EST, 11/06/2024 (MT Newswires) -- ...

    • 4:35PM ET on Wednesday Nov 06, 2024 by Dow Jones
      Companies Mentioned: PAHC
      ---------------------- ------- ------- ------------- (in millions, except percentages) Net Sales MFAs and other $ 107.8 $ 94.1 $ 13.7 15% Nutritional specialties 42.6 40.2 2.4 6% Vaccines 32.0 26.2 5.8 22% ------ ------ Animal Health 182.5 160.5 22.0 14% Mineral Nutrition 59.1 56.0 3.0 5% Performance Products 18.8 14.8 4.1 27% ------ ------ Total $ 260.4 $ 231.3 $ 29.1 13% ====== ====== Adjusted EBITDA Animal Health $ 40.4 $ 28.5 $ 11.9 42% Mineral Nutrition 3.8 2.9 0.9 31% Performance Products 2.3 1.4 0.9 62% Corporate (15.8) (14.1) (1.6) (12)% ------ ------ Total $ 30.7 $ 18.7 $ 12.0 64% ====== ====== Ratio to segment net sales Animal Health 22.1% 17.7% Mineral Nutrition 6.4% 5.1% Performance Products 12.1% 9.5% Corporate (1) (6.1)% (6.1)% Total (1) 11.8% 8.1% Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA Net income (loss) $ 7.0 $ (8.0) $ 15.0 *% Interest expense, net 7.6 4.6 3.1 67% Provision (benefit) for income taxes 2.6 (4.0) 6.6 *% Depreciation and amortization 9.0 8.9 0.1 1% ------ ------ EBITDA 26.3 1.5 24.8 * Acquisition-related transaction costs 3.4 -- 3.4 * Phibro Forward income growth initiatives(2) 0.4 -- 0.4 * Stock-based compensation 0.2 0.1 0.1 * Pension settlement cost -- 10.4 (10.4) * Foreign currency losses, net 0.4 6.7 (6.3) * ------ ------ Adjusted EBITDA $ 30.7 $ 18.7 $ 12.0 64% ====== ====== Amounts and percentages may reflect rounding adjustments. * Calculation not meaningful (1) Reflects ratio to total net sales (2) Phibro Forward is a company-wide initiative focused on unlocking additional areas of revenue growth and cost savings. Phibro Animal Health Corporation Adjusted Net Income Three Months ------------------------------------------ For the Periods Ended September 30 2024 2023 Change -------------------- ------ ------ ------------------ (in millions, except per share amounts and percentages) Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income Net income (loss) $ 7.0 $(8.0) $ 15.0 * Acquisition-related intangible amortization (1) 1.7 1.7 (0.0) (1)% Acquisition-related intangible amortization (2) 0.6 0.8 (0.2) (20)% Acquisition-related transaction costs (2) 3.4 -- 3.4 * Pension settlement cost (2) -- 10.4 (10.4) * Stock-based compensation (2) 0.2 0.1 0.1 * Phibro Forward income growth initiatives (2) 0.4 -- 0.4 * Refinancing expense (3) 2.0 -- 2.0 * Foreign currency losses, net (4) 0.4 6.7 (6.3) * Adjustments to income taxes (5) (1.5) (6.1) 4.6 (75)% ----- ----- Adjusted net income $ 14.1 $ 5.5 $ 8.5 * ===== ===== Statement of Operations Line Items - adjusted Adjusted cost of goods sold (1) $175.3 $162.0 $ 13.3 8% Adjusted gross profit 85.1 69.4 15.7 23% Adjusted selling, general and administrative (2) 61.2 57.2 4.1 7% Adjusted interest expense, net (3) 5.7 4.6 1.1 24% ----- ----- Adjusted income before income taxes 18.2 7.7 10.6 *% Adjusted provision for income taxes (5) 4.2 2.1 2.0 97% ----- ----- Adjusted net income $ 14.1 $ 5.5 $ 8.5 * ===== ===== Adjusted net income per share diluted $ 0.35 $ 0.14 $ 0.21 * Weighted average common shares outstanding diluted 40.6 40.5 Ratio to net sales Adjusted gross profit 32.7% 30.0% Adjusted selling, general and administrative 23.5% 24.7% Adjusted income before income taxes 7.0% 3.3% Adjusted net income 5.4% 2.4% Adjusted effective tax rate 22.8% 27.6% Amounts and percentages may reflect rounding adjustments. * Calculation not meaningful (1) Adjusted cost of goods sold excludes acquisition-related intangible amortization. (2) Adjusted selling, general and administrative excludes acquisition-related intangible amortization, acquisition-related transaction costs, pension settlement cost, stock-based compensation and costs associated with Phibro Forward income growth initiatives. (3) Refinancing expense includes third-party costs and the write-off of unamortized debt issuance costs related to the refinancing of the Company's credit facility in July 2024. (4) Foreign currency losses, net, are excluded from adjusted net income. (5) Adjusted provision for income taxes excludes the income tax effect of pre-tax income (loss) adjustments and certain income tax items.

Peers Headlines